Markets:

Overview

News

Currencies

International

Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

100.88 +2.51 (+2.55%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 Million ↗

October 21, 2025

Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 Million

Via The Motley Fool

Topics Regulatory Compliance

Big Pharma Just Put Peptides Back on the Map – Which Players Are Still Under the Radar?

October 20, 2025

Via AB Newswire

2 Top Dividend Kings Every Income Investor Should Own ↗

October 20, 2025

These companies pay durable and steadily rising dividends.

Via The Motley Fool

Topics Bonds

Johnson & Johnson's M&A Strategy Is the Real Story for Investors ↗

October 18, 2025

Johnson & Johnson’s rumored Protagonist buyout demonstrates its proven M&A strategy: divesting low-growth units to fund high-margin, innovative assets.

Via MarketBeat

BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In ↗

October 14, 2025

Via Stocktwits

Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook ↗

October 14, 2025

Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion orthopedics business, DePuy Synthes.

Via Benzinga

Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print ↗

October 14, 2025

Investors may also look for updates on J&J’s reported talks to acquire Protagonist Therapeutics to bolster its immunology and oncology pipeline.

Via Stocktwits

Topics Government World Trade

Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch ↗

October 13, 2025

Johnson & Johnson stock trades near all-time highs with an upcoming Q3 earnings report acting as the next catalyst.

Via Benzinga

FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy ↗

October 13, 2025

FDA updates Johnson & Johnson's Carvykti label to warn of rare immune-related enterocolitis while reaffirming the therapy's overall benefit.

Via Benzinga

Wall Street Suffers Worst Day Since April as Trump Revives Trade War Fears ↗

October 13, 2025

U.S. markets were rattled on Friday after President Trump reignited trade tensions with China, triggering the sharpest sell-off since April. Tech and AI stocks led the decline, while gold and...

Via Chartmill

Topics Artificial Intelligence Government World Trade

Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today ↗

October 10, 2025

The company could soon be swallowed by a very large peer -- which also happens to be a business partner.

Via The Motley Fool

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

October 10, 2025

Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 10, 2025

Via Benzinga

Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report ↗

October 10, 2025

Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its immunology and cancer drug portfolio.

Via Benzinga

Which stocks are experiencing notable movement on Friday? ↗

October 10, 2025

Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

5 Analysts Assess Protagonist Therapeutics: What You Need To Know ↗

October 08, 2025

Via Benzinga

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill

October 07, 2025

Via ACCESS Newswire

Demystifying Protagonist Therapeutics: Insights From 4 Analyst Reviews ↗

September 17, 2025

Via Benzinga

Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials ↗

September 17, 2025

Johnson & Johnson and Protagonist Therapeutics announced new data from their Phase 3 studies to treat severe plaque psoriasis.

Via Benzinga

This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

September 17, 2025

Via Benzinga

Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress

September 17, 2025

Via ACCESS Newswire

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025

September 15, 2025

Via ACCESS Newswire

This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗

September 12, 2025

Via Benzinga

Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency

September 11, 2025

Via ACCESS Newswire

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025

August 26, 2025

Via ACCESS Newswire

Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera

August 25, 2025

Via ACCESS Newswire

What 4 Analyst Ratings Have To Say About Protagonist Therapeutics ↗

August 07, 2025

Via Benzinga

Protagonist (PTGX) Q2 Revenue Falls 26% ↗

August 07, 2025

Via The Motley Fool

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 06, 2025

Via ACCESS Newswire

Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis

July 21, 2025

Via ACCESS Newswire

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.